Loading viewer...
conference
Format: PDF conference
Nektar Therapeutics presented at Cowen & Company's 37th Annual Healthcare Conference in March 2017, highlighting its biopharmaceutical pipeline including ONZEALD for metastatic breast cancer, NKTR-181 abuse-deterrent opioid, and NKTR-214 IL-15 agonist. The company outlined integrated R&D capabilities across facilities in San Francisco, Huntsville, and Hyderabad, with projected revenue of $375-450M annually by 2021 from its partnered portfolio.
investor_presentation
31 Pages
conference
55 Pages
Deloitte
Blueknight Energy Partners 2016 Citi MLP Midstream Conference
conferenceconference
26 Pages
Blueknight Energy Partners
South Jersey Industries 2017 Morgan Stanley Utilities Conference
conferenceconference
20 Pages
South Jersey Industries
California Resources Corporation 2017 Institutional Investors Conference
conferenceconference
49 Pages
California Resources Corporation